Fortress Biotech, Inc. (FBIO)
| Market Cap | 304.61M |
| Revenue (ttm) | 44.27M |
| Net Income (ttm) | -42.98M |
| Shares Out | 80.85M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $3.23 |
| Previous Close | $3.21 |
| Change ($) | 0.02 |
| Change (%) | 0.72% |
| Day's Open | 3.15 |
| Day's Range | 3.11 - 3.24 |
| Day's Volume | 96,414 |
| 52-Week Range | 2.12 - 6.10 |
The FDA refused to approve IV tramadol for the second time.
Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...
These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzi...
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing...
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney d...
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.
Investors were not thrilled with the company's latest regulatory update.
Investors need to pay close attention to Fortress Biotech (FBIO) stock based on the movements in the options market lately.
Fortress Biotech (FBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizin...
SCOTTSDALE, Ariz. and NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announc...
Fortress Biotech Inc's (NASDAQ: FBIO) partner company Journey Medical Corporation has agreed to acquire Qbrexza (glycopyrronium) in the U.S. from Dermira Inc, a wholly-owned subsidiary of Eli Lilly And ...
The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine-years of age and older is Journey Medical's seventh marketed dermatology product The first...
Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019
Accutane is Journey Medical's sixth marketed dermatology product Accutane is Journey Medical's sixth marketed dermatology product
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penny Stocks To Buy With Price Targets Up To 168% According To Analysts Maxim Group & H.C. Wainwright.
BORDENTOWN, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today annou...
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizin...
Fortress Biotech Inc's (NASDAQ: FBIO) partner company, Cyprium Therapeutics Inc, has agreed to sell CUTX-101 to Sentynl Therapeutics Inc. CUTX-101 is a copper histidinate product candidate for the treat...
Catherine Bowes Rickman, Ph.D., FARVO, a leading age-related macular degeneration researcher, appointed to Scientific Advisory Board
LOS ANGELES--(BUSINESS WIRE)---- $FBIO #FBIO--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $FBIO #FBIO--DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc.
New York, New York--(Newsfile Corp. - January 25, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decembe...
NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and Oct...
LOS ANGELES--(BUSINESS WIRE)---- $FBIO #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fortress Biotech, Inc. (FBIO)
LOS ANGELES, Jan. 22, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fortress Biotech, Inc. ("Fortress" o...
New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) a...
New York, New York--(Newsfile Corp. - January 18, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decembe...
New York, New York--(Newsfile Corp. - January 11, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decembe...
NEW YORK, Jan. 9. 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and Octo...
New York, New York--(Newsfile Corp. - January 6, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December...
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizin...
NEW YORK, Jan. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) and certain of its o...
LOS ANGELES, Dec. 30, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fortress Biotech, Inc. ("Fortress" o...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020,...
New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) ...
New York, New York--(Newsfile Corp. - December 26, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decem...
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and Oct...
One of the company's subsidiaries announced some good news today.
New York, New York--(Newsfile Corp. - December 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress Biot...
New York, New York--(Newsfile Corp. - December 14, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) ...
New York, New York--(Newsfile Corp. - December 13, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decemb...
BENSALEM, Pa.--(BUSINESS WIRE)---- $FBIO #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in Class Action Lawsuit Against Fortress Biotech, Inc. (FBIO)
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intra... [Read more...]
| Industry Biotechnology | Founded 2006 |
| CEO Lindsay Rosenwald | Employees 111 |
| Stock Exchange NASDAQ | Ticker Symbol FBIO |
Financial Performance
In 2020, FBIO's revenue was $45.60 million, an increase of 24.49% compared to the previous year's $36.63 million. Losses were -$46.53 million, 16.4% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is 10.17, which is an increase of 214.57% from the latest price.